National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Victoza®  is indicated for treatment of adults with type 2 diabetes mellitus.

 

NCPE Assessment Process Ongoing
Rapid review received 01/09/2009
Rapid review completed 07/10/2009
Rapid Review outcome Full pharmacoeconomic evaluation not recommended

 

 The HSE has now requested a full HTA for this product 26 October 2016
Full pharmacoeconomic assessment commissioned by HSE 26/10/2016
Pre-submission consultation with Applicant 21/02/2017
Submission received from Applicant 07/09/2017
Preliminary review sent to Applicant 17/08/2018
NCPE assessment re-commenced 30/10/2018
Factual accuracy sent to Applicant 07/02/2019
Current status Awaiting response from Applicant